Published in Thromb Res on January 05, 2012
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J (2015) 1.09
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Can Fam Physician (2014) 1.07
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol (2016) 0.87
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital. Eur J Clin Pharmacol (2014) 0.78
Analgesic use before and after oral anticoagulant initiation--a population-based study in Finland. Eur J Clin Pharmacol (2015) 0.77
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol (2013) 0.75
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis (2013) 2.71
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thromb Haemost (2012) 1.94
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res (2012) 1.58
The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg (2007) 1.55
Postoperative myocardial damages after hip fracture repair are frequent and associated with a poor cardiac outcome: a three-hospital study. Age Ageing (2009) 1.48
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res (2013) 1.37
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost (2009) 1.14
Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly. Int Orthop (2010) 1.08
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res (2007) 1.08
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Perioperative mortality in hip fracture patients treated with cemented and uncemented hemiprosthesis: a register study of 11,210 patients. Int Orthop (2013) 0.95
Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol (2010) 0.94
The ''critical thrombosis period'' in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost (2009) 0.94
An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica (2006) 0.94
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med (2002) 0.90
Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res (2012) 0.88
Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg (2002) 0.87
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost (2007) 0.87
Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Crit Rev Oncol Hematol (2011) 0.86
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost (2003) 0.85
Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int (2010) 0.85
Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials. Thromb Haemost (2011) 0.84
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis (2011) 0.84
Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology (2004) 0.83
Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int (2005) 0.83
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res (2012) 0.82
Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty (2011) 0.82
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. Eur J Clin Pharmacol (2012) 0.81
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Pathophysiol Haemost Thromb (2006) 0.81
How can we explain the gap between randomised studies and 'real life' practice in postoperative transfusion triggers? Do we need to change recommended thresholds for transfusion? Eur J Anaesthesiol (2012) 0.80
The proportion of perioperative mortalities attributed to cemented implantation in hip fracture patients treated by hemiarthroplasty. Hip Int (2014) 0.79
Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. Thromb Haemost (2012) 0.79
Biochemical lung, liver and kidney markers and early death among elderly following hip fracture. Arch Orthop Trauma Surg (2012) 0.79
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thromb Res (2012) 0.79
D-Dimer and prothrombin fragment 1 + 2 in urine and plasma in patients with clinically suspected venous thromboembolism. Blood Coagul Fibrinolysis (2016) 0.79
Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. Thromb Res (2013) 0.78
The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. BJU Int (2007) 0.78
Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ) (2010) 0.77
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res (2008) 0.77
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin. Thromb Haemost (2004) 0.77
Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs (2004) 0.77
The population attributable risk of nutrition and lifestyle on hip fractures. Hip Int (2015) 0.77
Tranexamic acid for trauma. Lancet (2010) 0.77
Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis. Can J Urol (2005) 0.76
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety. Clin Drug Investig (2005) 0.76
Early administration of tranexamic acid in trauma patients. Lancet (2011) 0.75
Vardenafil in patients with erectile dysfunction: achieving treatment optimization. J Androl (2005) 0.75
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs. Thromb Haemost (2010) 0.75
Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. Ann Pharmacother (2005) 0.75
Neither pre-operative education or a minimally invasive procedure have any influence on the recovery time after total hip replacement. Int Orthop (2015) 0.75
Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. J Sex Med (2004) 0.75
[Thromboprophylaxis in surgical patients]. Presse Med (2013) 0.75
Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis. Can J Anaesth (2006) 0.75
Rate of Improvement in Clinical Outcomes with Anatomic and Reverse Total Shoulder Arthroplasty. J Bone Joint Surg Am (2017) 0.75